H00017 | |
H number | H00017 |
Name | Esophageal cancer |
Description | Esophageal cancer represents the 9th leading cancer in the world and is associated with a 5-year survival rate under 25%. The two main forms are squamous-cell carcinoma (ESCC) and adenocarcinoma (EAC). ESCC is the most frequent histological subtype in esophageal cancer, although the incidence of EAC is increasing faster than any other malignancy in the western world. Whereas ESCC can be attributed to alcohol and tobacco consumption, the most important risk factor for the development of EAC is duodenal-gastric-esophageal reflux. In the process of tumorigenesis at the cellular level, multiple genetic alterations are involved, including mutation of the p53 gene, amplification of cyclin D1 gene, among others. |
Category | Cancer |
Network | - |
Gene | EGFR (overexpression) [HSA:1956] [KO:K04361] PTGS2 (overexpression) [HSA:5743] [KO:K11987] NOS2 (increased expression) [HSA:4843] [KO:K13241] FAS (increased expression) [HSA:355] [KO:K04390] CCND1 (amplification) [HSA:595] [KO:K04503] TP53 [HSA:7157] [KO:K04451] CDKN2A [HSA:1029] [KO:K06621] RB1 [HSA:5925] [KO:K06618] APC [HSA:324] [KO:K02085] DCC [HSA:1630] [KO:K06765] LZTS1 [HSA:11178] [KO:K26460] RNF6 [HSA:6049] [KO:K22753] TGFBR2 [HSA:7048] [KO:K04388] WWOX [HSA:51741] [KO:K19329] |
Pathogen | - |
Env factor | - |
Carcinogen | - |
Drug | Capecitabine [DR:D01223] Floxuridine [DR:D04197] Nivolumab [DR:D10316] Pembrolizumab [DR:D10574] (PD-L1 expressed) Porfimer sodium [DR:D03327] |
Comment | - |
Other DBs | ICD-11: 2B70 ICD-10: C15 MeSH: D004938 OMIM: 133239 |
Reference | PMID:15622457 (EGFR, TP53, PTGS2, NOS2, CCND1, CDKN2A, RB1) AUTHORS Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M, Fukai Y, Sohda M, Kimura H, Faried A. TITLE Genetic alterations in esophageal cancer. JOURNAL Surg Today 35:7-18 (2005) DOI:10.1007/s00595-004-2885-3 PMID:12951586 (APC, CDKN2A, NOS2, RB1, PTGS2, TP53, RB1, EGFR, FAS) AUTHORS Wild CP, Hardie LJ. TITLE Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. JOURNAL Nat Rev Cancer 3:676-84 (2003) DOI:10.1038/nrc1166 PMID:15914317 (CCND1, TP53, RB1, CDKN2A, APC, WWOX, FAS) AUTHORS McCabe ML, Dlamini Z. TITLE The molecular mechanisms of oesophageal cancer. JOURNAL Int Immunopharmacol 5:1113-30 (2005) DOI:10.1016/j.intimp.2004.11.017 PMID:8187090 (DCC) AUTHORS Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y TITLE Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. JOURNAL Cancer Res 54:3007-10 (1994) PMID:11504921 (LZTS1) AUTHORS Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM TITLE FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. JOURNAL Proc Natl Acad Sci U S A 98:10374-9 (2001) DOI:10.1073/pnas.181222898 PMID:12154016 (RNF6) AUTHORS Lo HS, Hu N, Gere S, Lu N, Su H, Goldstein AM, Taylor PR, Lee MP TITLE Identification of somatic mutations of the RNF6 gene in human esophageal squamous cell carcinoma. JOURNAL Cancer Res 62:4191-3 (2002) PMID:10789724 (TGFBR2) AUTHORS Tanaka S, Mori M, Mafune K, Ohno S, Sugimachi K TITLE A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma. JOURNAL Br J Cancer 82:1557-60 (2000) DOI:10.1054/bjoc.1999.1178 PMID:11956080 (WWOX) AUTHORS Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M, Croce CM TITLE Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. JOURNAL Cancer Res 62:2258-60 (2002) |